The DOI matches its Crossref record; 379 of the 379 references it cites were found in a registry or an index.
Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies
Open accessAbstract
Osteosarcoma is the most common primary malignant bone tumour in children and adolescents. Due to micrometastatic spread, radical surgery alone rarely results in cure. Introduction of combination chemotherapy in the 1970s, however, dramatically increased overall survival rates from 20% to approximately 70%. Unfortunately, large clinical trials aiming to intensify treatment in the past decades have failed to achieve higher cure rates. In this review, we revisit how the heterogenous nature of osteosarcoma as well as acquired and intrinsic resistance to chemotherapy can account for stagnation in therapy improvement. We summarise current osteosarcoma treatment strategies focusing on molecular determinants of treatment susceptibility and resistance. Understanding therapy susceptibility and resistance provides a basis for rational therapy betterment for both identifying patients that might be cured with less toxic interventions and targeting resistance mechanisms to sensitise resistant osteosarcoma to conventional therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–379 of 379
Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal
Li, S., Sun, W. Y., Wang, H., Zuo, D., Hua, Y., & Cai, Z. (2015) · Tumor Biology · doi:10.1007/s13277-015-3181-0 · Cited by 105
Rose, A. A. N., Biondini, M., Curiel, R. E., & Siegel, P. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.010 · Cited by 105
The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma
Ehrlich, L. A., & Roodman, G. D. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00323.x · Cited by 100
Biller, B. J., Guth, A., Burton, J. H., & DOW, S. W. (2010) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2010.0557.x · Cited by 100
Wnt Pathway in Osteosarcoma, from Oncogenic to Therapeutic
Cai, Y., Cai, T., & Chen, Y. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24708 · Cited by 99
Schwartz, C. L., Wexler, L. H., Krailo, M., Teot, L. A., Devidas, M., Steinherz, L. J., Goorin, A. M., Gebhardt, M. C., Healey, J. H., Sato, J. K., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25753 · Cited by 99
Cell surface receptor expression patterns in osteosarcoma
Hassan, S. E., Bekarev, M., Kim, M., Lin, J., Piperdi, S., Gorlick, R. G., & Geller, D. S. (2011) · Cancer · doi:10.1002/cncr.26339 · Cited by 99
Frontline treatment of localized osteosarcoma without methotrexate
Daw, N. C., Neel, M. D., Rao, B. N., Billups, C. A., Wu, J., Jenkins, J. J., Quintana, J. A., Luchtman‐Jones, L., Milena Villarroel, C., & Santana, V. M. (2011) · Cancer · doi:10.1002/cncr.25715 · Cited by 99
Palmerini, E., Jones, R. L., Marchesi, E., Paioli, A., Cesari, M., Longhi, A., Meazza, C., Coccoli, L., Fagioli, F., Asaftei, S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2312-3 · Cited by 98
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
Laverdière, C., Kolb, E. A., Supko, J. G., Gorlick, R. G., Meyers, P. A., Maki, R. G., Wexler, L. H., Demetri, G. D., Healey, J. H., Huvos, A. G., et al. (2003) · Cancer · doi:10.1002/cncr.11563 · Cited by 98
Longhi, A., Ferrari, S. M., Bacci, G., & Specchia, S. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32803d36fe · Cited by 97
Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
Gordon, E. M., Sankhala, K. K., Chawla, N. S., & Chawla, S. P. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0344-3 · Cited by 97
Liu, T., Li, Z., Zhang, Q., Bernstein, K. D. A., Lozano‐Calderón, S. A., Choy, E., Hornicek, F. J., & Duan, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.13148 · Cited by 96
Clézardin, P. (2013) · BoneKEy Reports · doi:10.1038/bonekey.2013.1 · Cited by 95
Anderson, P. M., Bielack, S., Gorlick, R. G., Skubitz, K. M., Daw, N. C., Herzog, C. E., Monge, O. R., Lassaletta, Á., Boldrini, É., Pápai, Z., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26087 · Cited by 95
Dobson, S. M., García-Prat, L., Vanner, R. J., Wintersinger, J., Waanders, E., Gu, Z., McLeod, J., Gan, O. I., Grandal, I., Payne-Turner, D., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1059 · Cited by 94
Fiore, R. D., Santulli, A., Ferrante, R. D., Giuliano, M., Blasio, A. D., Messina, C. M., Pirozzi, G., Tirino, V., Tesoriere, G., & Vento, R. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21667 · Cited by 94
MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study
Wunder, J. S., Bull, S. B., Aneliunas, V., Lee, P. D., Davis, A. M., Beauchamp, C. P., Conrad, E. U., Grimer, R. J., Healey, J. H., Rock, M. J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2685 · Cited by 94
Engert, F., Kovac, M. B., Baumhoer, D., Nathrath, M., & Fulda, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10720 · Cited by 94
Resistance Mechanisms to Methotrexate in Tumors
Bertino, J. R., Göker, E., Gorlick, R. G., Li, W. W., & Banerjee, D. (1996) · Stem Cells · doi:10.1002/stem.140005 · Cited by 93
Avnet, S., Lemma, S., Cortini, M., Pellegrini, P., Perut, F., Zini, N., Kusuzaki, K., Chano, T., Grisendi, G., Dominici, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11503 · Cited by 92
Ratti, C., Botti, L., Cancila, V., Galvan, S., Torselli, I., Garofalo, C., Manara, M. C., Bongiovanni, L., Valenti, C. F., Burocchi, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3186 · Cited by 91
Patiño‐García, A., Zalacaín, M., Marrodán, L., San-Julián, M., & Sierrasesúmaga, L. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.11.030 · Cited by 89
Prognostic value of inflammation-based scores in patients with osteosarcoma
Liu, B., Huang, Y., Sun, Y., Zhang, J., Yao, Y., Shen, Z., Xiang, D., & He, A. (2016) · Scientific Reports · doi:10.1038/srep39862 · Cited by 89
Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma
Wang, Q., Lu, Y., Li, R., Jiang, Y., Zheng, Y., Qian, J., Bi, E., Zheng, C., Hou, J., Wang, S., et al. (2017) · Leukemia · doi:10.1038/leu.2017.193 · Cited by 89
Park, H. J., Bae, J. S., Kim, K. M., Moon, Y. J., Park, S., Ha, S. H., Hussein, U. K., Zhang, Z., Park, H. S., Park, B., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0772-9 · Cited by 89
CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models
Xu, J.-F., Pan, X.-H., Zhang, S.-J., Zhao, C., Qiu, B.-S., Gu, H.-F., Hong, J.-F., Cao, L., Chen, Y., Xia, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4282 · Cited by 88 · cited 10×
“In human osteosarcoma, M2-TAMs are linked to metastasis and poor survival, whereas M1 polarization correlates with nonmetastatic disease and better survival [59,60].”
BackgroundInfluentialKilpatrick, S. E., Geisinger, K. R., King, T. S., Sciarrotta, J., Ward, W. G., Gold, S., & Bos, G. D. (2001) · Modern Pathology · doi:10.1038/modpathol.3880474 · Cited by 88
Loss of Osteoclasts Contributes to Development of Osteosarcoma Pulmonary Metastases
Endo‐Munoz, L., Cumming, A., Rickwood, D., Wilson, D., Cueva, C., Ng, C. K. Y., Strutton, G., Cassady, A. I., Evdokiou, A., Sommerville, S. M. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4291 · Cited by 88
Arndt, C. A. S., Koshkina, N., Inwards, C. Y., Hawkins, D. S., Krailo, M., Villaluna, D., Anderson, P. M., Goorin, A. M., Blakely, M. L., Bernstein, M. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0662 · Cited by 87
Mu, X., Isaac, C. E., Greco, N., Huard, J., & Weiss, K. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00143 · Cited by 87
p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3
Wong, R. P. C., Tsang, W. P., Chau, P. Y., Co, N. N., Tsang, T. Y., & Kwok, T. T. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0336 · Cited by 87
Genome-wide analyses on high-grade osteosarcoma: Making sense of a genomically most unstable tumor
Kuijjer, M. L., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28124 · Cited by 84
Increased osteoclast activity is associated with aggressiveness of osteosarcoma
Avnet, S. (1992) · International Journal of Oncology · doi:10.3892/ijo_00000113 · Cited by 84
Müller, C. R., Smeland, S., Bauer, H. C. F., Sæter, G., & Strander, H. A. (2005) · Acta Oncologica · doi:10.1080/02841860510029978 · Cited by 84
Wang, Y., Han, X., Qiu, Y., Xiong, J., Yu, Y., Wang, B., Zhu, Z., Qian, B., Chen, Y., Wang, S., et al. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22077 · Cited by 83
Ototoxicity in children treated for osteosarcoma
Lewis, M., DuBois, S. G., Fligor, B. J., Li, X., Goorin, A. M., & Grier, H. E. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21875 · Cited by 83
Kolb, E. A., Kamara, D., Zhang, W., Lin, J., Hingorani, P., Baker, L. H., Houghton, P. J., & Gorlick, R. G. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22479 · Cited by 83
Sulzbacher, I., Birner, P., Trieb, K., Träxler, M., Lang, S., & Chott, A. (2003) · Modern Pathology · doi:10.1097/01.mp.0000043522.76788.0a · Cited by 81
Ferrari, S., Bertoni, F., Zanella, L., Setola, E., Bacchini, P., Alberghini, M., Versari, M., & Bacci, G. (2004) · Cancer · doi:10.1002/cncr.20151 · Cited by 81
Inhibition of Metastatic Behavior of Murine Osteosarcoma by Hypophysectomy
Pollak, M., Sem, A., Richard, M., Tetenes, E., & Bell, R. S. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.12.966 · Cited by 81
Adjuvant chemotherapy of osteosarcoma.
Eilber, F. R., & Rosen, G. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.6.982 · Cited by 79
Kopp, L. M., Malempati, S., Krailo, M., Gao, Y., Buxton, A. B., Weigel, B. J., Hawthorne, T. R., Crowley, E. M., Moscow, J. A., Reid, J. M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.015 · Cited by 79
Anderson, P. M., Meyers, P. A., Kleinerman, E. S., Venkatakrishnan, K., Hughes, D. P. M., Herzog, C. E., Huh, W. W., Sutphin, R. M., Vyas, Y. M., Shen, V., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24686 · Cited by 77
Phase II trial of ifosfamide in children with malignant solid tumors.
Pratt, C. B., Horowitz, M. E., Meyer, W. H., Etcubanas, E., Thompson, E. I., Douglass, E. C., Wilimas, J. A., Hayes, F. A., & Green, A. A. (1987) · PubMed · Cited by 77
Chen, R., Wang, G., Zheng, Y., Hua, Y., & Cai, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14064 · Cited by 77
Surgical management of adrenal metastases from lung cancer
Beitler, A. L., Urschel, J. D., Velagapudi, S., & Takita, H. (1998) · Journal of Surgical Oncology · doi:10.1002/(sici)1096-9098(199809)69:1<21::aid-jso5>3.0.co;2-m · Cited by 75
Krailo, M., Ertel, I. J., Makley, J. T., Fryer, C. J., Baum, E. S., Weetman, R. M., Yunis, E. J., Barnes, L. E., Bleyer, W. A., & Hammond, G. D. (1987) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950150205 · Cited by 75
Gupte, A., Baker, E. K., Wan, S.-S., Stewart, E. A., Loh, A. H. P., Shelat, A. A., Gould, C. M., Chalk, A. M., Taylor, S., Lackovic, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3026 · Cited by 74
Sevelda, F., Mayr, L., Kubista, B., Lötsch, D., van Schoonhoven, S., Windhager, R. H., Pirker, C., Micksche, M., & Berger, W. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0251-5 · Cited by 74
Prognostic Significance of TP53 Tumor Suppressor Gene Expression and Mutations in Human Osteosarcoma
Pakos, E. E., Kyzas, P., & Ioannidis, J. P. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0246 · Cited by 71
Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis
Eliseev, R. A., Dong, Y.-F., Sampson, E. R., Zuscik, M. J., Schwarz, E. M., O’Keefe, R. J., Rosier, R. N., & Drissi, H. (2008) · Oncogene · doi:10.1038/sj.onc.1211020 · Cited by 70
Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas
Anninga, J., van de Vijver, M. J., Cleton-Jansen, A., Kristel, P., Taminiau, A. H. M., Nooij, M. A., Egeler, R. M., & Hogendoorn, P. C. W. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.10.025 · Cited by 70
Paulides, M., Kremers, A., Stöhr, W., et al. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20492 · Cited by 69
The role of interferons in the treatment of osteosarcoma
Whelan, J., Patterson, D., Perisoglou, M., Bielack, S., Marina, N. M., Smeland, S., & Bernstein, M. L. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22136 · Cited by 69
Livin and Bcl-2 expression in high-grade osteosarcoma
Nedelcu, T., Kubista, B., Koller, A., Sulzbacher, I., Mosberger, I., Arrich, F., Trieb, K., Kotz, R. I., & Toma, C. D. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0276-z · Cited by 69
An update on emerging drugs in osteosarcoma: towards tailored therapies?
Hattinger, C. M., Patrizio, M. P., Magagnoli, F., Luppi, S., & Serra, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1654455 · Cited by 68
Nucleotide Excision Repair in Eukaryotes
Goosen, N. (2013) · Encyclopedia of Biological Chemistry · doi:10.1016/b978-0-12-378630-2.00491-6 · Cited by 67
Blattmann, C., Oertel, S., Schulz–Ertner, D., Rieken, S., Haufe, S., Ewerbeck, V., Unterberg, A. W., Karapanagiotou‐Schenkel, I., Combs, S. E., Nikoghosyan, A. V., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-96 · Cited by 66
Harned, T. M., Kalous, O., Neuwelt, A. J., Loera, J., Ji, L., Iovine, P. M., Sposto, R., Neuwelt, E. A., & Reynolds, C. P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2289 · Cited by 65
Yang, R. R., Kolb, E. A., Qin, J., Chou, A. J., Sowers, R. S., Hoang, B. H., Healey, J. H., Huvos, A. G., Meyers, P. A., & Gorlick, R. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1343 · Cited by 65
High‐dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity
Berrak, S. G., Pearson, M. G., Berberoĝlu, S., İlhan, İ. E., & Jaffe, N. (2004) · Pediatric Blood & Cancer · doi:10.1002/pbc.20228 · Cited by 61
Lampson, B. L., & Davids, M. S. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0359-0 · Cited by 61
Giaccone, G., & Pinedo, H. M. (1996) · The Oncologist · doi:10.1634/theoncologist.1-1-82 · Cited by 61
Combination Chemotherapy in Cancer: Principles, Evaluation and Drug Delivery Strategies
Catarina, A., Nuno, J., & Simões, S. (2011) · InTech eBooks · doi:10.5772/22656 · Cited by 60
Berger, M., Grignani, G., Ferrari, S., Biasin, E., Adalberto, B. D. P., Sandra, A., Saglio, F., Aglietta, M., & Franca, F. (2009) · Cancer · doi:10.1002/cncr.24368 · Cited by 60
Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis
Wen, Y. H., Koeppen, H., Garcia, R., Chiriboga, L. A., Tarlow, B., Peters, B. A., Eigenbrot, C. W., Yee, H. T., Steiner, G. C., & GRECO, M. A. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.01.002 · Cited by 60
Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma
Nogueira, P. C. K., Hadj‐Aïssa, A., Schell, M., Dubourg, L. D., Brunat-Mentigny, M., & Cochat, P. (1998) · Pediatric Nephrology · doi:10.1007/s004670050507 · Cited by 59
Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses
Sottnik, J. L., U’Ren, L., Thamm, D. H., Withrow, S. J., & DOW, S. W. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0755-y · Cited by 58
Serra, M., Pasello, M., Manara, M. C., Scotlandi, K., Ferrari, S., Bertoni, F., Mercuri, M., Alvegård, T. A., Picci, P., Bacci, G., et al. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.6.1459 · Cited by 58
Roth, M. E., Barris, D. M., Piperdi, S., Kuo, V. F.-H., Everts, S., Geller, D., Houghton, P. J., Kolb, E. A., Hawthorne, T. R., Gill, J. B., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25688 · Cited by 58
Rudd, S. G., Tsesmetzis, N., Sanjiv, K., Paulin, C. B. J., Sandhow, L., Kutzner, J., Myrberg, I. H., Bunten, S. S., Axelsson, H., Zhang, S. M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910419 · Cited by 58
Self-citationMultiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line
Rajkumar, T., & Yamuna, M. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f435b6 · Cited by 57
Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples.
Yang, R. R., Sowers, R. S., Mazza, B., Healey, J. H., Huvos, A. G., Grier, H. E., Bernstein, M. L., Beardsley, G. P., Krailo, M., Devidas, M., et al. (2003) · PubMed · Cited by 57
Huang, G., Mills, L., & Worth, L. L. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0580 · Cited by 56
Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring Cancer
Goulart, M. R., Pluhar, G. E., & Ohlfest, J. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033274 · Cited by 55
Cancer stem cells in osteosarcoma: Recent progress and perspective
Liu, B., Ma, W., Jha, R. K., & Gurung, K. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.584553 · Cited by 55
Pleiotropic effects of bisphosphonates on osteosarcoma
Ohba, T., Cates, J., Cole, H., Slosky, D., Haro, H., Ichikawa, J., Ando, T., Schwartz, H. S., & Schoenecker, J. G. (2014) · Bone · doi:10.1016/j.bone.2014.03.005 · Cited by 55
Cyclooxygenase-2 Expression in Pediatric Sarcomas
Dickens, D. S., Kozielski, R., Khan, J. I., Forus, A., & Cripe, T. P. (2002) · Pediatric and Developmental Pathology · doi:10.1007/s10024-002-0005-1 · Cited by 55
Yang, J., Yang, D., Cogdell, D. E., Du, X., Li, H., Pang, Y., Sun, Y. K., Hu, L., Sun, B., Trent, J. C., et al. (2010) · Technology in Cancer Research & Treatment · doi:10.1177/153303461000900205 · Cited by 53
Association of Loss of Heterozygosity at the p53 Locus with Chemoresistance in Osteosarcomas
Goto, A., Kanda, H., Ishikawa, Y., Matsumoto, S., Kawaguchi, N., Machinami, R., Kato, Y., & Kitagawa, T. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb03295.x · Cited by 53
Sowers, R. S., Toguchida, J., Qin, J., Meyers, P. A., Healey, J. H., Huvos, A. G., Banerjee, D., Bertino, J. R., & Gorlick, R. G. (2003) · PubMed · Cited by 53
Li, X., Liu, Y., Zhang, X., Shen, J., Xu, R., Liu, Y., & Xiao, Y. (2020) · Aging · doi:10.18632/aging.103423 · Cited by 53
Navet, B., Ando, K., Vargas-Franco, J. W., Brion, R., Amiaud, J., Mori, K., Yagita, H., Mueller, C. G., Verrecchia, F., Dumars, C., et al. (2018) · Cancers · doi:10.3390/cancers10110398 · Cited by 52
Culp, W. T. N., Olea‐Popelka, F. J., Sefton, J., Aldridge, C. F., Withrow, S. J., Lafferty, M. H., Rebhun, R. B., Kent, M. S., & Ehrhart, N. P. (2014) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.245.10.1141 · Cited by 52
Reduced folate carrier protein expression in osteosarcoma
Ifergan, I., Meller, I., Isakov, J., & Assaraf, Y. G. (2003) · Cancer · doi:10.1002/cncr.11741 · Cited by 51
Identification of drug‐regulated genes in osteosarcoma cells
Fellenberg, J., Dechant, M. J., Ewerbeck, V., & Mau, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11135 · Cited by 51
Modulation of Cisplatinum Cytotoxicity by p53: Effect of p53-Mediated Apoptosis and DNA Repair
Fan, J., & Bertino, J. R. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.5.966 · Cited by 51
李, 潤. (2000) · Medical Entomology and Zoology · doi:10.11501/3171115 · Cited by 51
Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma
Lo, W. W., Wunder, J. S., Dickson, B. C., Campbell, V. T., McGovern, K., Alman, B. A., & Andrulis, I. L. (2013) · Cancer · doi:10.1002/cncr.28439 · Cited by 50
Zhao, Y., Zhang, C.-L., Zeng, B.-F., Wu, X.-S., Gao, T.-T., & Oda, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.020 · Cited by 50
Somers, G. R., Ho, M., Zieleńska, M., Squire, J. A., & Thorner, P. S. (2005) · Pediatric and Developmental Pathology · doi:10.1007/s10024-005-0044-5 · Cited by 50
Wiegering, A., Matthes, N., Mühling, B., Koospal, M., Quenzer, A., Peter, S., Germer, C.-T., Linnebacher, M., & Otto, C. (2017) · Neoplasia · doi:10.1016/j.neo.2017.01.007 · Cited by 50
Control of Blood Vessel Formation by Notch Signaling.
Tetzlaff, F., & Fischer, A. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-89512-3_16 · Cited by 50
Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi, K., Perdichizzi, S., Manara, M. C., Serra, M., Benini, S., Cerisano, V., Strammiello, R., Mercuri, M., Reverter‐Branchat, G., Faircloth, G. T., et al. (2002) · PubMed · Cited by 49
RECQ DNA Helicases and Osteosarcoma
Lu, L., Jin, W., Liu, H., & Wang, L. L. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_7 · Cited by 48
Yang, L., Li, X., & Bao, C.-F. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.11.5883 · Cited by 48
Interventions for cisplatin-induced hearing loss in children and adolescents with cancer
Freyer, D. R., Brock, P. R., Knight, K. R., Reaman, G. H., Cabral, S., Robinson, P. D., & Sung, L. (2019) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(19)30115-4 · Cited by 48
Mohanty, S., Aghighi, M., Yerneni, K., Theruvath, J. L., & Daldrup-Link, H. E. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12556 · Cited by 48
Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma
Wu, H., Zhang, J., Dai, R., Xu, J., & Feng, H. (2019) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-019-1301-z · Cited by 47
Rousseau, J., Escriou, V., Lamoureux, F., Brion, R., Chesneau, J., Battaglia, S., Amiaud, J., Scherman, D., Heymann, D., Rédiní, F., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.455 · Cited by 45
Targeting hedgehog‐GLI‐2 pathway in osteosarcoma
Yang, W., Liu, X., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2012) · Journal of Orthopaedic Research® · doi:10.1002/jor.22230 · Cited by 45
Liu, S., Zhi, Y., Ling, M., Shi, J., Qiu, Y., & Yang, S. (2014) · Tumor Biology · doi:10.1007/s13277-014-1917-x · Cited by 45
Mutations in p53, p53 protein overexpression and breast cancer survival
Rössner, P., Gammon, M. D., Zhang, Y., Terry, M. B., Hibshoosh, H. H., Memeo, L., MANSUKHANI, M. M., Long, C., Garbowski, G. C., Agrawal, M., et al. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00553.x · Cited by 45
Long-Term Adjuvant Interferon Treatment of Human Osteosarcoma: A pilot study
Strander, H. A., Bauer, H. C. F., Brosjö, O., Fernberg, J.-O., Andris Kreicbergs, A., Nilsonne, U., Silfverswärd, C., Signomklao, T., & Söderlund, V. (1995) · Acta Oncologica · doi:10.3109/02841869509127199 · Cited by 45
for the Children’s Oncology Group, Kopp, L. M., Womer, R. B., Schwartz, C. L., Ebb, D. H., Franco, V. I., Hall, D. C., Barkauskas, D. A., Krailo, M., Grier, H. E., et al. (2019) · Cardio-Oncology · doi:10.1186/s40959-019-0050-9 · Cited by 45
Inherited germline ATRX mutation in two brothers with ATR‐X syndrome and osteosarcoma
Ji, J., Quindipan, C., Parham, D. M., Shen, L., Ruble, D., Bootwalla, M., Maglinte, D. T., Gai, X., Saitta, S. C., Biegel, J. A., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38184 · Cited by 44
Profiling targetable immune checkpoints in osteosarcoma
McEachron, T. A., Triche, T. J., Sorenson, L., Parham, D. M., & Carpten, J. D. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1475873 · Cited by 44
Kolb, E. A., Gorlick, R. G., Billups, C. A., Hawthorne, T. R., Kurmasheva, R. T., Houghton, P. J., & Smith, M. A. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25099 · Cited by 43
Fanelli, M., Tavanti, E., Patrizio, M. P., Vella, S., Fernandez-Ramos, A., Magagnoli, F., Luppi, S., Hattinger, C. M., & Serra, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00331 · Cited by 43
Paget disease: when to treat and when not to treat
Singer, F. R. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.149 · Cited by 42
Human osteosarcoma xenografts and their sensitivity to chemotherapy
Bruheim, S., Bruland, Ø. S., Breistøl, K., Mælandsmo, G. M., & Fodstad, Ø. (2004) · Pathology & Oncology Research · doi:10.1007/bf03033741 · Cited by 42
Piperno-Neumann, S., Ray-Coquard, I. L., Occéan, B., Laurence, V., Cupissol, D., Perrin, C., Penel, N., Bompas, E., Rios, M., Cesne, A. L., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32526 · Cited by 42
Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma?
Lee, J. A., Ko, Y., Kim, D. H., Lim, J. S., Kong, C., Cho, W. H., Jeon, D., Lee, S., & Koh, J.-S. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.3.202 · Cited by 41
Wang, D., Zhong, Z., Li, M., Xiang, D., & Zeng-peng, L. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00616.x · Cited by 40
Baud’huin, M., Renault, R., Charrier, C., Riet, A. V., Brion, R., Moreau, A., Gouin, F., Duplomb, L., & Heymann, D. (2010) · Bone · doi:10.1016/j.bone.2010.04.314 · Cited by 40
Kersting, C., Gebert, C., Agelopoulos, K., Schmidt, H., van Diest, P. J., Juergens, H., Winkelmann, W., Kevric, M., Gosheger, G., Brandt, B., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2432 · Cited by 40
Bacci, G., Picci, P., Ferrari, S., et al. (1993) · Journal of Chemotherapy · doi:10.1080/1120009x.1993.11739239 · Cited by 40
Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Fruci, D., Cho, W. C. S., Romania, P., Nobili, V., Locatelli, F., & Alisi, A. (2016) · Current Drug Metabolism · doi:10.2174/1567205010666131212110948 · Cited by 39
Daw, N. C., Neel, M. D., Rao, B. N., Billups, C. A., Wu, J., Jenkins, J. J., Milena Villarroel, C., Luchtman‐Jones, L., Quintana, J., & Santana, V. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.10036 · Cited by 38
Houghton, P. J., Kurmasheva, R. T., Kolb, E. A., Gorlick, R. G., Maris, J. M., Wu, J., Tong, Z., Arnold, M., Chatterjee, M., Williams, T. M., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25474 · Cited by 37
Sex- and Age-Related Chemotherapy Toxicity in Patients with Non-Metastatic Osteosarcoma
Ferrari, S. M., Palmerini, E., Staals, E. L., Abate, M. E., Longhi, A., Cesari, M., Balladelli, A., Pratelli, L., & Bacci, G. (2009) · Journal of Chemotherapy · doi:10.1179/joc.2009.21.2.205 · Cited by 35
Rosen, G., Nirenberg, A., Caparros, B., Juergens, H., Kosloff, C., Mehta, B. M., Marcove, R. C., & Ag, H. (1981) · PubMed · Cited by 35
Ding, L., Wang, C., Cui, Y., Han, X., Zhou, Y., Bai, J., & Li, R. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4345 · Cited by 35
Kolb, E. A., Gorlick, R. G., Keir, S. T., Maris, J. M., Lock, R. B., Carol, H., Kurmasheva, R. T., Reynolds, C. P., Kang, M. H., Wu, J., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23290 · Cited by 32
Chen, Y., Zhang, K.-S., Li, Y., Guo, R., Zhang, K., Zhong, G., & He, Q. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14123 · Cited by 32
Cheng, Z.-X., Guo, Y., Yang, Y., Kan, J., Dai, S., Helian, M., Li, B., Xu, J., & Liu, C. (2016) · Oncology Reports · doi:10.3892/or.2016.4846 · Cited by 31
Isakoff, M. S., Goldsby, R. E., Villaluna, D., Krailo, M., Hingorani, P., Collier, A. B., Morris, C. D., Kolb, E. A., Doski, J. J., Womer, R. B., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27524 · Cited by 31
Complexities in Interpretation of Osteosarcoma Clinical Trial Results
Hunsberger, S., Freidlin, B., & Smith, M. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3484 · Cited by 30
Xu, M., Xu, S., & Yu, X. (2014) · Current Oncology · doi:10.3747/co.21.1973 · Cited by 30
Assi, H. I., Missenard, G., Terrier, P., Pechoux, C. L., Bonvalot, S., Vanel, D., Méric, J., Tursz, T., & Cesne, A. L. (2010) · Current Oncology · doi:10.3747/co.v17i6.578 · Cited by 30
Viglietta, V., Shi, F., Hu, Q.-Y., Ren, Y., Keilty, J., Wolff, H. M., McCarthy, R., Kropp, J. T., Weber, P., & Soglia, J. R. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00918-1 · Cited by 30
Yang, C., Gao, R., Wang, J., Yuan, W., Wang, C., & Zhou, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-1833-0 · Cited by 29
Improved Survival in Osteosarcoma Patients with Atypical Low Vascularization
Kunz, P., Fellenberg, J., Moskovszky, L. E., Sápi, Z., Krenács, T., Machado, I., Poeschl, J., Lehner, B., Szendrői, M., Ruef, P., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4001-2 · Cited by 29
Chen, P., Wang, H., Duan, Z., Zou, J. X., Chen, H.-W., He, W., & Wang, J. (2014) · BioMed Research International · doi:10.1155/2014/616025 · Cited by 29
Luk, F., Yu, Y. Y., Walsh, W. R., et al. (2011) · Cancer Investigation · doi:10.3109/07357907.2011.606252 · Cited by 29
Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas
Asano, N., Takeshima, H., Yamashita, S., Takamatsu, H., Hattori, N., Kubo, T., Yoshida, A., Kobayashi, E., Nakayama, R. T., Matsumoto, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56883-0 · Cited by 29
Ji, W., & He, N. (2015) · Europe PMC (PubMed Central) · Cited by 28
Liu, J., Wu, J., Zhou, L., Pan, C., Zhou, Y., Du, W., Chen, J., Zhu, X., Shen, J., Chen, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4179 · Cited by 28
Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein
Wu, D., Liu, L., Yan, X., Wang, C., Wang, Y., Han, K., Lin, S., Gan, Z., & Min, D. (2017) · Oncotarget · doi:10.18632/oncotarget.19148 · Cited by 28
Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas
Flintoff, W. F., Sadlish, H., Gorlick, R. G., Yang, R. R., & Williams, F. M. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.05.008 · Cited by 27
Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma
Bishop, M. W., & Janeway, K. A. (2016) · F1000Research · doi:10.12688/f1000research.8228.1 · Cited by 27
Lancia, C., Anninga, J., Sydes, M. R., Spitoni, C., Whelan, J. S., Hogendoorn, P. C. W., Gelderblom, H. A. J., & Fiocco, M. F. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03797-3 · Cited by 27
Kaji, H., Sugimoto, T., Kanatani, M., Nishiyama, K., Nasu, M., & Chihara, K. (1997) · Journal of Cellular Physiology · Cited by 26
Hattinger, C. M., Michelacci, F., Sella, F., Magagnoli, G., Benini, S., Gambarotti, M., Palmerini, E., Picci, P., Serra, M., & Ferrari, S. (2015) · Histopathology · doi:10.1111/his.12653 · Cited by 24
The development of PARP as a successful target for cancer therapy
Ferrara, R., Simionato, F., Ciccarese, C., Grego, E., Cingarlini, S., Iacovelli, R., Bria, E., Tortora, G., & Melisi, D. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1419870 · Cited by 24
Bisphosphonates in common pediatric and adult bone sarcomas
Heymann, M., Lézot, F., & Heymann, D. (2020) · Bone · doi:10.1016/j.bone.2020.115523 · Cited by 24
Giaccone, G., & Pinedo, H. M. (1996) · PubMed · Cited by 24
Tsuchiya, H., Mori, Y., Ueda, Y., Okada, G., & Tomita, K. (2000) · PubMed · Cited by 23
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
Holme, H., Gulati, A., Brough, R., Fleuren, E. D. G., Bajrami, I., Campbell, J., Chong, I. Y.-S., Costa-Cabral, S., Elliott, R. J. R., Fenton, T. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29043-z · Cited by 23
Pre‐clinical evaluation of proteasome inhibitors for canine and human osteosarcoma
Patatsos, K., Shekhar, T. M., & Hawkins, C. J. (2018) · Veterinary and Comparative Oncology · doi:10.1111/vco.12413 · Cited by 22
Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis
Liu, X., Zhang, Z., Deng, C., Tian, Y., & Ma, X. (2017) · Oncotarget · doi:10.18632/oncotarget.19370 · Cited by 21
TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma
Tao, Y., Xin, M., Cheng, H.-C., Huang, Z., Hu, T., Zhang, T., & Wang, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.7059 · Cited by 21
MicroRNA-765 sensitizes osteosarcoma cells to cisplatin via downregulating APE1 expression
Wei, L., Li, C., Li, M., Wang, D., & Zhong, Z. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194800 · Cited by 20
Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma
Xiao, X., Wang, W., Zhang, H., Gao, P., Fan, B., Huang, C., Fu, J., Chen, G., Shi, L., Zhu, H., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2853-5 · Cited by 19
Polymorphisms and Methylation of the Reduced Folate Carrier in Osteosarcoma
Yang, R., Qin, J., Hoang, B. H., Healey, J. H., & Gorlick, R. G. (2008) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-008-0323-3 · Cited by 19
Response of refractory osteosarcoma to thalidomide and celecoxib
Tsai, Y., Wu, C., & Hong, R. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70468-x · Cited by 19
Gao, Y., Liao, Y., Shen, J. K., Feng, Y., Choy, E., Cote, G. M., Harmon, D. C., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2016) · Journal of Orthopaedic Research® · doi:10.1002/jor.23173 · Cited by 19
Bhuvaneshwar, K., Harris, M. A., Gusev, Y., Madhavan, S., Iyer, R. K., Vilboux, T., Deeken, J. F., Yang, E., & Shankar, S. M. (2019) · BMC Cancer · doi:10.1186/s12885-019-5474-y · Cited by 19
Basile, P., Greengard, E. G., Weigel, B. J., & Spector, L. G. (2020) · Sarcoma · doi:10.1155/2020/7431549 · Cited by 18
Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies
Liu, Y., Ma, Y., Sun, Z.-Z., Rui, Y., Yin, Q., da Song, S., Wei, X.-M., Liu, J., Liu, X., & Hu, K. (2014) · Tumor Biology · doi:10.1007/s13277-014-2165-9 · Cited by 17
Hattinger, C. M., Vella, S., Tavanti, E., Fanelli, M., Picci, P., & Serra, M. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0116 · Cited by 17
Obiedat, H., Alrabadi, N., Sultan, E., Al-Shatti, M., & Zihlif, M. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0627-4 · Cited by 16
SKA 1 induces de novo MTX ‐resistance in osteosarcoma through inhibiting FPGS transcription
Yu, W., Min, D., Feng, L., Zheng, S., Tang, L., He, A., Hu, H., & Shen, Z. (2019) · FEBS Journal · doi:10.1111/febs.14808 · Cited by 15
Marec‐Bérard, P., Laurence, V., Occéan, B., et al. (2019) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2019.0085 · Cited by 15
Adjuvant interferon treatment in human osteosarcoma
Strander, H. A., Bauer, H. C. F., Brosjö, O., Andris Kreicbergs, A., Lindholm, J., Nilsonne, U., Silfverswärd, C., & Szamosi, A. (1993) · Cancer treatment and research · doi:10.1007/978-1-4615-3518-8_5 · Cited by 13
SPC24 promotes osteosarcoma progression by increasing EGFR/MAPK signaling
Sheng, J., Yin, M., Sun, Z., Kang, X., Liu, D., Jiang, K., Xu, J. X., Zhao, F., Guo, Q., & Zheng, W. (2017) · Oncotarget · doi:10.18632/oncotarget.22167 · Cited by 13
Hattinger, C. M., Patrizio, M. P., Luppi, S., Magagnoli, F., Picci, P., & Serra, M. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1588885 · Cited by 13
HER2-Targeted Therapy in Osteosarcoma
Gill, J. B., Hingorani, P., Roth, M. E., & Gorlick, R. G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_5 · Cited by 13
Perioperative chemotherapy with and without high-dose methotrexate in adult osteosarcoma
Negrao, M. V., Rocha, L. S. D. S., Girardi, D. M., & Feher, O. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000533 · Cited by 11
Shimizu, T., Fuchimoto, Y., Okita, H., Fukuda, K., Kitagawa, Y., Ueno, S., & Kuroda, T. (2018) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2018.08.023 · Cited by 11
Herold, N. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1811672 · Cited by 11
Self-citationElucidating the mechanisms of action of parecoxib in the MG-63 osteosarcoma cell line
Lemos, S., Sampaio‐Marques, B., Ludovico, P., Gaivão, I., Palmeira, C., Martins, G., Peixoto, F., Pinto‐Leite, R., & Oliveira, P. A. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000901 · Cited by 9
Lancia, C., Anninga, J., Spitoni, C., Sydes, M. R., Whelan, J. S., Hogendoorn, P. C. W., Gelderblom, H. A. J., & Fiocco, M. F. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022980 · Cited by 8
Kang, J., Ju, H. Y., Joo, J., Sung, J. Y., Park, S. Y., Kim, J. H., Kang, H. G., Kwon, M., Park, M., Park, H. J., et al. (2019) · Oncology · doi:10.1159/000502548 · Cited by 7
Afatinib is active in osteosarcoma in osteosarcoma cell lines
Cruz‐Ramos, M., Zamudio-Cuevas, Y. E., Medina-Luna, D., Martínez‐Flores, K., Martínez‐Nava, G. A., Fernández‐Torres, J., López-Reyes, A. G., & Solca, F. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03220-y · Cited by 7
A Review of Dysregulated Osteoblast and Osteoclast Coupling in Bone Disease and Failure
Visconti, R. P., Iversen, T., & Cottrell, J. A. (2019) · Journal of Bone Research · Cited by 6
Detection and significance of glutathione-S-transferase pi in osteogenic tumors of dogs
Shoieb, A. M., & Hahn, K. A. (1997) · International Journal of Oncology · doi:10.3892/ijo.10.3.635 · Cited by 5
Pathway enrichment analysis of human osteosarcoma U-2 OS bone cells expose to dexamethasone.
Chen, J., Ji, X., Sq, W., Yb, W., Jg, W., Chen, F.-Y., Gy, H., & Js, S. (2014) · PubMed · Cited by 4
Cited by
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Systematic Review of Recurrent Osteosarcoma Systemic Therapy
Gazouli, I., Kyriazoglou, A., Kotsantis, I., Anastasiou, M., Pantazopoulos, A., Prevezanou, M., Chatzidakis, I., Kavourakis, G., Economopoulou, P., Kontogeorgakos, V., et al. (2021) · Cancers · doi:10.3390/cancers13081757 · Cited by 63
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
Landuzzi, L., Manara, M. C., Lollini, P.-L., & Scotlandi, K. (2021) · Cells · doi:10.3390/cells10020416 · Cited by 39
Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma
Wu, K., Yu, B., Li, D., Tian, Y., Liu, Y., & Jiang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.805978 · Cited by 39
Metadata
- Authors
- Lilienthal, I., & Herold, N.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-09-19
- Volume
- 21
- Issue
- 18
- Pages
- 6885
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3087198975
- Cited by
- 283
- References
- 379
- FWCI
- 18.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.